In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $MREO Mereo BioPharma and its Phase Three ORBIT and COSMIC trials for setrusumab in osteogenesis imperfecta. We break down Phase Two bone mineral density data, missed fracture reduction endpoints, interim analysis results, the eighty seven percent stock collapse, and alleged misleading statements about clinical confidence. This deep dive is for biotech investors, healthcare traders, and anyone following rare disease drug development, clinical trial risk, and securities litigation news.

Visit ZLK.com for more info.

Add our WhatsApp Channel